NASDAQ · ARCT
Healthcare · Biotechnology
$15.84
Down-$0.07 (-0.44%)
Updated Sep 16, 2026, 5:12 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ARCT closed at $15.84 after 20 trading sessions, up 92.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $15.335 | $15.99 | $14.755 | $15.84 | 556.18K |
| Sep 14, 2026 | $14.62 | $15.53 | $14.42 | $15.29 | 596.19K |
| Sep 11, 2026 | $14.06 | $15.1242 | $14.06 | $14.73 | 496.64K |
| Sep 10, 2026 | $14.29 | $14.33 | $13.12 | $13.98 | 944K |
| Sep 9, 2026 | $15.46 | $15.46 | $14.46 | $14.74 | 723.05K |
| Sep 8, 2026 | $15.47 | $15.855 | $14.765 | $15.63 | 641.47K |
| Sep 4, 2026 | $15.61 | $16.02 | $15.40 | $15.82 | 534.62K |
| Sep 3, 2026 | $16.77 | $16.99 | $15.34 | $15.56 | 849.07K |
| Sep 2, 2026 | $16.46 | $17.7497 | $15.45 | $16.74 | 2.02M |
| Sep 1, 2026 | $14.87 | $16.85 | $14.8575 | $16.225 | 1.37M |
| Aug 31, 2026 | $15.00 | $15.65 | $14.00 | $14.76 | 1.26M |
| Aug 28, 2026 | $15.43 | $15.90 | $14.491 | $15.19 | 1.62M |
| Aug 27, 2026 | $15.74 | $16.59 | $15.43 | $16.17 | 1.13M |
| Aug 26, 2026 | $15.35 | $16.49 | $14.73 | $15.83 | 2.23M |
| Aug 25, 2026 | $14.12 | $16.24 | $14.12 | $15.44 | 2.21M |
| Aug 24, 2026 | $13.325 | $14.53 | $12.42 | $14.34 | 2.41M |
| Aug 21, 2026 | $11.13 | $13.50 | $11.11 | $13.45 | 2.86M |
| Aug 20, 2026 | $10.08 | $11.4736 | $10.061 | $10.99 | 2.29M |
| Aug 19, 2026 | $9.405 | $11.10 | $9.33 | $10.28 | 5.63M |
| Aug 18, 2026 | $8.03 | $8.49 | $8.03 | $8.21 | 403.15K |
The latest Smart Investors Daily articles mentioning ARCT.
ARCT research
Company profile and research snapshot.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 2, 2026 | Freedom Broker | Buy | — |
| Mar 18, 2026 | B. Riley Securities | Buy | — |
| Mar 5, 2026 | Citigroup | Buy | — |
| Mar 4, 2026 | Piper Sandler | Overweight | — |
| Mar 4, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Arcturus Therapeutics Holdings Inc. (ARCT) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 9:20 AM EDTCompany ParticipantsJoseph Payne -...
Yahoo · Aug 31, 2026
SAN DIEGO, August 31, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences:
Yahoo · Aug 27, 2026
Is it a good or bad thing when a stock experiences a golden cross technical event?
Benzinga · Aug 20, 2026
Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ARCT.
